Grigg J, Worsley R, Thew C, Gurvich C, Thomas N, Kulkarni J
Psychopharmacology (Berl). 2017; 234(22):3279-3297.
PMID: 28889207
DOI: 10.1007/s00213-017-4730-6.
Zhornitsky S, Stip E
Schizophr Res Treatment. 2012; 2012:407171.
PMID: 22966436
PMC: 3420751.
DOI: 10.1155/2012/407171.
Koola M, Wehring H, Kelly D
J Dual Diagn. 2012; 8(1):50-61.
PMID: 22754405
PMC: 3383636.
DOI: 10.1080/15504263.2012.647345.
Br J Pharmacol. 1982; 77 Suppl:445P-597P.
PMID: 7150878
PMC: 2044581.
Br J Pharmacol. 1983; 78 Suppl:1P-187P.
PMID: 6831120
PMC: 2044687.
A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency.
Wistedt B, Jorgensen A, Wiles D
Psychopharmacology (Berl). 1982; 78(4):301-4.
PMID: 6818587
DOI: 10.1007/BF00433729.
The effect of propranolol on CSF amine metabolites in psychiatric patients.
King D, Cooper S, Liddle J
Br J Clin Pharmacol. 1983; 15(3):331-7.
PMID: 6189502
PMC: 1427775.
DOI: 10.1111/j.1365-2125.1983.tb01507.x.
A depot neuroleptic withdrawal study neurological effects.
Wistedt B, Wiles D, Jorgensen A
Psychopharmacology (Berl). 1983; 80(2):101-5.
PMID: 6136059
DOI: 10.1007/BF00427950.
Characteristics of oral movements in rats during and after chronic haloperidol and fluphenazine administration.
See R, Levin E, Ellison G
Psychopharmacology (Berl). 1988; 94(3):421-7.
PMID: 3128820
DOI: 10.1007/BF00174701.
Clinical pharmacokinetics of the depot antipsychotics.
Jann M, Ereshefsky L, Saklad S
Clin Pharmacokinet. 1985; 10(4):315-33.
PMID: 2864156
DOI: 10.2165/00003088-198510040-00003.
Amphetamine response and relapse risk after depot neuroleptic discontinuation.
Angrist B, Peselow E, Rubinstein M, WOLKIN A, Rotrosen J
Psychopharmacology (Berl). 1985; 85(3):277-83.
PMID: 2860683
DOI: 10.1007/BF00428187.
